HOME >> BIOLOGY >> NEWS
Other highlights in the September 21 JNCI

Study Reports Elevated Risk of Second Cancers for Testicular Cancer Survivors

Men who survive testicular cancer have an increased risk of developing a second cancer for at least 35 years after diagnosis, according to the largest study to date of testicular cancer survivors.

Testicular cancer largely affects young men, and the 10-year survival rate of the disease is as high as 95%, so most men survive testicular cancer. However, these men have an increased risk of developing second cancers, mostly because of the late side effects of treatment. These cancers are a leading cause of death for testicular cancer patients.

To determine the risks of second cancers among long-term survivors of testicular cancer, Lois B. Travis, M.D., of the National Cancer Institute, and colleagues examined data from 40,576 1-year survivors of testicular cancer from population-based tumor registries in Europe and North America. A total of 2,285 second solid cancers were reported among these men anywhere from 1 year to more than 35 years after their testicular cancer diagnosis.

Ten-year survivors who had been diagnosed with testicular cancer at age 35 had a risk of developing a second cancer that was nearly twice that of the general population, and this risk remained elevated for 35 years. Risks were higher for patients diagnosed with testicular cancer at younger ages and lower for patients diagnosed at older ages. Cancers of the bladder, colon, lung, pancreas, and stomach accounted for 60% of the total excess risk. The authors conclude that testicular cancer survivors are at increased risk of solid tumors for at least 35 years after treatment and that young patients may face high levels of risk as they get older.

Contact: National Cancer Institute Press Office, 301-496-6641, NCIPressOfficers@mail.nih.gov

Hormone Replacement Therapy Associated With Increases in Mammographic Breast Den
'"/>

Contact: Sarah L. Zielinski
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Sep-2005


Page: 1 2 3 4 5

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights from the June 6 JNCI
7. Other highlights in the May 16 JNCI
8. Other highlights from the April 18 Journal of the National Cancer Institute
9. Other highlights from the March 21 JNCI
10. Other highlights in the March 7 JNCI
11. Other highlights in the Feb. 21 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other highlights the September JNCI

(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
Cached News: